SavedAdd your journal

Journals / Ege Tıp Dergisi / 2021 / Cilt: 60 - Sayı: Supplement

Treatment decision in patient with ankylosing spondylitis in remission

Remisyonda olan ankilozan spondilit hastasında tedavi kararı

Hüseyin Turgut Elbek Özer
Pages
49–52
Publication Date
2022-10-17
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Physical therapy is also recommended after the remission.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Non-steroidal anti-inflammatory drugs (NSAIDs) may attain 9 to 35% remission rates in patients with ankylosing spondylitis, this rate may rise to 16 to 62% in anti-TNF users.
📊
Key Findings & Data:Following withdrawal of biologics there is 47 to 76% relapse rate in one year.
💡
Conclusion & Impact:Physical therapy is also recommended after the remission.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Non-steroidal anti-inflammatory drugs (NSAIDs) may attain 9 to 35% remission rates in patients with ankylosing spondylitis, this rate may rise to 16 to 62% in anti-TNF users. Following withdrawal of biologics there is 47 to 76% relapse rate in one year. Dose reduction or standard dosing of anti-TNF therapies yields comparable rates of remission maintenance in one year (53.5% vs. 61.4%). NSAIDs have shown to retard radiologic progression and decrease mortality in AS patients. NSAIDs should be used on demand in stable patients. Physical therapy is also recommended after the remission.

Özet

Ankilozan spondilitte non-steroid anti-inflamatuvar ilaçlarda (NSAİİ) %9-35’e varan oranlarda anti-TNF ajanlarında %16-62 oranlarında remisyon sağlandığı görülmüştür. Biyolojik ilaç kesimini takiben bir yıl içerisinde hastalarda %47-76 oranlarında relaps görülmüştür. Remisyon sonrası doz azaltılması, tam doz tedavi devamı ile karşılaştırıldığında benzer oranlarda remisyon sürdürülmüştür (%53,5’e karşı %61,4). Ankilozan spondilitte NSAİİ’ın kullanımının radyolojik progresyonu gerilettiği ve azalmış mortalite ile ilişkili olduğu gösterilmiştir. NSAİİ’ın gerektiği durumlarda kullanılması önerilmektedir. Egzersiz programlarına remisyon sonrasında da devam edilmelidir.

🔖

Cite This Article

Özer, H. T. E. (2022). Treatment decision in patient with ankylosing spondylitis in remission. Ege Tıp Dergisi, Cilt: 60 - Sayı: Supplement, 49–52. https://ajindex.com/articles/496001

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (8)

  1. Poddubnyy D, Gensler LS. Spontaneous, drug-induced, and drug-free remission in peripheral and axial spondyloarthritis. Best Pract Res Clin Rheumatol 2014 Oct; 28 (5): 807-18. 2. van der Heijde D, Baraf HS, Ramos-Remus C, et al. Evaluation of the efficacy of etoricoxib in ankylosing spondylitis: results of a fifty-two-week, randomized, controlled study. Arthritis Rheum 2005; 52: 1205-15
  2. Sieper J, Lenaerts J, Wollenhaupt J, et al. Efficacy and safety of infliximab plus naproxen versus naproxen alone in patients with early, active axial spondyloarthritis: results from the double-blind, placebo-controlled INFAST study, Part 1. Ann Rheum Dis 2014; 73: 101-7. 4. van der Heijde D, Dijkmans B, Geusens P, et al. Efficacy and safety of infliximab in patients with ankylosing spondylitis: results of a randomized, placebo-controlled trial (ASSERT) Arthritis Rheum 2005;52:582-91
  3. Davis JC, Jr, Van Der Heijde D, Braun J, et al. Recombinant human tumor necrosis factor receptor (etanercept) for treating ankylosing spondylitis: a randomized, controlled trial. Arthritis Rheum 2003; 48: 3230-6. 6. van der Heijde D, Kivitz A, Schiff MH, et al. Efficacy and safety of adalimumab in patients with ankylosing spondylitis: results of a multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2006; 54: 2136-46
  4. Inman RD, Davis JC, Jr, Heijde D, et al. Efficacy and safety of golimumab in patients with ankylosing spondylitis: results of a randomized, double-blind, placebo-controlled, phase III trial. Arthritis Rheum 2008; 58: 3402-12
  5. Landewé R, Braun J, Deodhar A, et al. Efficacy of certolizumab pegol on signs and symptoms of axial spondyloarthritis including ankylosing spondylitis: 24-week results of a double-blind randomised placebo- controlled Phase 3 study. Ann Rheum Dis 2014; 73 (1):39-47
  6. Barkham N, Keen HI, Coates LC, et al. Clinical and imaging efficacy of infliximab in HLA-B27-Positive patients with magnetic resonance imaging-determined early sacroiliitis. Arthritis Rheum 2009; 60: 946-54
  7. Song IH, Althoff CE, Haibel H, et al. Frequency and duration of drug-free remission after 1 year of treatment with etanercept versus sulfasalazine in early axial spondyloarthritis: 2 year data of the ESTHER trial. Ann Rheum Dis 2012; 71: 1212-5
  8. Sieper J, van der Heijde D, Dougados M, et al. Efficacy and safety of adalimumab in patients with non- radiographic axial spondyloarthritis: results of a randomised placebo-controlled trial (ABILITY